Hepatocellular carcinoma
ICD-10 C22.0 · ICD-11 2C12.02

Solitary Early-Stage HCC ≤5 cm — What to Do After Local Ablation Did Not Achieve Complete Response

This protocol addresses patients with a solitary early-stage hepatocellular carcinoma measuring 5 cm or less who are ineligible for or declining surgical resection, and who have received local ablative therapy but did not achieve the required endpoint on post-treatment imaging.

Clinical Scenario

Patients with a solitary hepatocellular carcinoma ≤5 cm who cannot undergo or decline surgery are candidates for curative-intent local ablation. When post-ablation contrast-enhanced imaging shows viable residual tumor — indicating that complete response was not achieved — the clinical situation calls for a structured next step.

Previous Treatment & Escalation Trigger

The prior line was local ablative therapy with curative intent — thermal ablation (radiofrequency or microwave) as the preferred approach for tumors ≤3 cm, with targeted radioembolization or external beam radiation therapy (including stereotactic body radiation or proton beam) as alternatives, including for tumors larger than 3 cm. The therapeutic goal was complete response with no viable residual tumor on post-ablation contrast-enhanced imaging. Failure to reach this endpoint is the indication for the next-line protocol.

Next-Step Approach (Partial Overview)

For patients determined to be at high risk of recurrence following local ablation, adjuvant immune checkpoint inhibitor-based systemic therapy is the approach outlined in this protocol. The full regimen — including the specific agents, eligibility criteria, timing of initiation, and duration — is detailed in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

View source ↗